论文部分内容阅读
Primary cutaneous B cell lymphomas have a high recurrence rate after treatment with surgery and/or local radiation therapy. Two men are described in whom radi otherapy-relapsing cutaneous B-cell lymphomas were successfully treated with t he monoclonal anti-CD20 antibody rituximab. Both patients had a complete respon se with no recurrence at follow-up at 17 and 24 months for the large B-cell ly mphoma of the leg and the follicle centre cell lymphoma, respectively. These are two of the few cases in the literature showing that rituximab is an effective and well-tolerated treatment for radio therapy-relapsing primary cutaneous B cell lymphoma.
Primary cutaneous B cell lymphomas have a high recurrence rate after treatment with surgery and / or local radiation therapy. Two men are described in whom radiotherapy-relapsing cutaneous B-cell lymphomas were successfully treated with t he monoclonal anti-CD20 antibody rituximab. Both patients had a complete response se with no recurrence at follow-up at 17 and 24 months for the large B-cell ly mphoma of the leg and the follicle center lymphoma, respectively. These are two of the few cases in the literature showing that rituximab is an effective and well-tolerated treatment for radio therapy-relapsing primary cutaneous B cell lymphoma.